title: A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus.
abstract: OBJECTIVE
  To obtain longitudinal data on growth/puberty in a large-scale, multi-national prospective cohort of juvenile systemic lupus erythematosus (SLE).
  
  
  METHODS
  Data from 331/557 (59.4%) patients ≤18 years old with juvenile SLE in active phase, with anthropometric data available at four follow-up visits, were studied.
  
  
  RESULTS
  There was a significant reduction in parent-adjusted height z score with time in females and males (p<0.0001), with a significant gender difference (p<0.0001) and with male height being most affected. Median body mass index z score peaked at 6 months and was still significantly above baseline after 26 months (p<0.01), with no gender difference. Standardised height reduction was inversely related to age at onset. Females with onset age <12 years had a median parent-adjusted height z score of -0.87 with no catch-up growth. At the end of the study, growth failure was seen in 14.7% of the females and 24.5% of the males. Height deflection (less than -0.25/year) was found in 20.7% of the females and 45.5% of the males. Delayed pubertal onset was seen in 15.3% and 24% of the females and males, respectively, and delayed/absent menarche was seen in 21.9%, while 36.1% of the females and 44% of the males had some degree of delayed pubertal development. Growth failure baseline determinants were previous growth failure (OR: 56.6), age at first visit ≤13.4 years (OR: 4.2) and cumulative steroid dose >426 mg/kg (OR: 3.6).
  
  
  CONCLUSIONS
  The children at risk of having a negative effect on height and pubertal development are prepubertal and peripubertal children treated with >400 mg/kg cumulative dose of corticosteroids.
authors: Faculty of medicine, Department of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway.
authors: Marite
authors: M
authors: Rygg
authors: Angela
authors: A
authors: Pistorio
authors: Angelo
authors: A
authors: Ravelli
authors: Mohamad
authors: M
authors: Maghnie
authors: Natascia
authors: N
authors: Di Iorgi
authors: Brigitte
authors: B
authors: Bader-Meunier
authors: Carlos
authors: C
authors: Da Silva
authors: Rosa
authors: R
authors: Roldan-Molina
authors: Judith
authors: J
authors: Barash
authors: Cristina
authors: C
authors: Dracou
authors: Sylvie Gandon
authors: SG
authors: Laloum
authors: Katerina
authors: K
authors: Jarosova
authors: Chantal Job
authors: CJ
authors: Deslandre
authors: Isabelle
authors: I
authors: Koné-Paut
authors: Franco
authors: F
authors: Garofalo
authors: Joseph
authors: J
authors: Press
authors: Claudia
authors: C
authors: Sengler
authors: Tsivia
authors: T
authors: Tauber
authors: Alberto
authors: A
authors: Martini
authors: Nicolino
authors: N
authors: Ruperto
mesh_terms: D000293:Adolescent; D017668:Age of Onset; D000886:Anthropometry / Q000379:methods; D001827:Body Height / Q000502:physiology; D015992:Body Mass Index; D002648:Child; D004334:Drug Administration Schedule; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects; D006128:Growth / Q000502:physiology; D006130:Growth Disorders / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D008137:Longitudinal Studies; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D011446:Prospective Studies; D011627:Puberty / Q000502:physiology; D011628:Puberty, Delayed / Q000209:etiology* / Q000503:physiopathology; D012737:Sex Factors
chemical_list: D005938:Glucocorticoids